uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Castration radiosensitizes prostate cancer tissue by impairing DNA double-strand break repair
Karolinska Inst, Dept Med Biochem & Biophys, Div Translat Med & Chem Biol, Sci Life Lab, S-17165 Stockholm, Sweden.;Cent Hosp Vasteras, Dept Urol, S-72189 Vasteras, Sweden..
Karolinska Inst, Dept Med Biochem & Biophys, Div Translat Med & Chem Biol, Sci Life Lab, S-17165 Stockholm, Sweden..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology.
Cent Hosp Vasteras, Dept Pathol, S-72189 Vasteras, Sweden..
Show others and affiliations
2015 (English)In: Science Translational Medicine, ISSN 1946-6234, E-ISSN 1946-6242, Vol. 7, no 312, 312re11Article in journal (Refereed) PublishedText
Abstract [en]

Chemical castration improves responses to radiotherapy in prostate cancer, but the mechanism is unknown. We hypothesized that this radiosensitization is caused by castration-mediated down-regulation of non-homologous end joining (NHEJ) repair of DNA double-strand breaks (DSBs). To test this, we enrolled 48 patients with localized prostate cancer in two arms of the study: either radiotherapy first or radiotherapy after neoadjuvant castration treatment. We biopsied patients at diagnosis and before and after castration and radiotherapy treatments to monitor androgen receptor, NHEJ, and DSB repair in verified cancer tissue. We show that patients receiving neoadjuvant castration treatment before radiotherapy had reduced amounts of the NHEJ protein Ku70, impaired radiotherapy-induced NHEJ activity, and higher amounts of unrepaired DSBs, measured by gamma-H2AX foci in cancer tissues. This study demonstrates that chemical castration impairs NHEJ activity in prostate cancer tissue, explaining the improved response of patients with prostate cancer to radiotherapy after chemical castration.

Place, publisher, year, edition, pages
2015. Vol. 7, no 312, 312re11
National Category
Cancer and Oncology
URN: urn:nbn:se:uu:diva-269976DOI: 10.1126/scitranslmed.aac5671ISI: 000365237300002OAI: oai:DiVA.org:uu-269976DiVA: diva2:885599
Swedish Research CouncilEU, European Research CouncilAFA InsuranceSwedish Cancer SocietyTorsten Söderbergs stiftelseAstraZeneca
Available from: 2015-12-19 Created: 2015-12-19 Last updated: 2015-12-19Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Tanoglidi, Anna
By organisation
Department of Immunology, Genetics and Pathology
In the same journal
Science Translational Medicine
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 51 hits
ReferencesLink to record
Permanent link

Direct link